
Novo Nordisk, Lundbeck and Ascendis Pharma count among the companies that have cause for celebration after this month's meeting at the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP).
The committee has thus nominated Novo Nordisk's weight loss drug Wegovy, Lundbeck's migraine infusion Vyepti and Ascendis Pharma's growth hormone Skytrofa for European patient use.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app